| Pharmaceutical Information |
| Drug Name |
Fluciclovine f-18 |
| Drug ID |
BADD_D00910 |
| Description |
Fluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging.[A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body.[A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049] |
| Indications and Usage |
Fluciclovine is indicated as a detection agent for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.[A31388] The overexpression of L-type amino acid transporters such as LAT1 and LAT3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growth.[A31389] |
| Marketing Status |
Prescription |
| ATC Code |
V09IX12 |
| DrugBank ID |
DB13146
|
| KEGG ID |
D10860
|
| MeSH ID |
C117460
|
| PubChem ID |
450601
|
| TTD Drug ID |
D03QIP
|
| NDC Product Code |
69932-001 |
| Synonyms |
fluciclovine F-18 | (1R,3R)-1-amino-3(18F)fluorocyclobutane-1-carboxylic acid | cyclobutanecarboxylic acid, 1-amino-3-(fluoro-18F)-, trans- | F(18)-FACBC | F(18)1-amino-3-fluorocyclobutane-1-carboxylic acid | anti-(18F)FACBC | fluciclovine F 18 | fluciclovine (18F) | 1-amino-3-fluorocyclobutane-1-carboxylic acid | F-FACBC | Axumin | GE-148 (18F) | GE-148 F-18 | (18F)GE-148 | NMK 36 | NMK36 cpd | NMK-36 |
|
| Chemical Information |
| Molecular Formula |
C5H8FNO2 |
| CAS Registry Number |
222727-39-1 |
| SMILES |
C1C(CC1(C(=O)O)N)F |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Dysgeusia | 17.02.07.003; 07.14.03.001 | - | - | | | Injection site erythema | 08.02.03.001; 23.03.06.015; 12.07.03.001 | - | - | Not Available | | Injection site pain | 12.07.03.011; 08.02.03.010 | - | - | Not Available |
|
The 1th Page
1
Total 1 Pages
|
|
